Key Takeaways
- • Citadel Advisors bought about 2.7 million AbbVie shares in the second quarter at an average price near $235, an outlay of roughly $633 million, lifting its holding to about 3.2 million shares from roughly half a million at the start of the quarter.
- • With AbbVie shares at about $284, Citadel's disclosed stake was worth roughly $909 million, about 21% above its average purchase price, according to the article's calculations.
- • The position represented less than half of one percent of Citadel's reported U.S. equity holdings at the end of June, and a 13F filing shows only long U.S. equity and certain options, so it may reflect a directional view, a paired trade, or a later-adjusted position.
- • AbbVie's post-Humira growth case rests on Skyrizi and Rinvoq, with Q2 2026 Skyrizi sales of about $5.5 billion and Rinvoq about $2.5 billion, and full-year revenue guidance raised twice to about $67.6 billion.
- • Key risks include immunology pricing pressure, concentration in Skyrizi and Rinvoq, weak aesthetics and Imbruvica sales, acquisition-related leverage, and a share price that already reflects much of the 2026 rally.
Summary
Citadel Advisors, the multi-strategy hedge fund led by Ken Griffin, made one of its more notable pharmaceutical moves of 2026 in the second quarter, buying about 2.7 million shares of AbbVie at an average price of roughly $235, an outlay of about $633 million, according to CEOWORLD magazine. The holding rose to about 3.2 million shares from roughly half a million at the start of the quarter. With AbbVie trading near $284, up about 24% year to date, the disclosed stake was worth about $909 million. At the end of June the position was less than half of one percent of Citadel's reported U.S. equity holdings.
The article cautions that quarterly 13F disclosures must be read carefully for a firm like Citadel, where dozens of independent portfolio teams run long and short positions that are often hedged against each other. A 13F reflects only long U.S. equity holdings and certain options at quarter-end, so the AbbVie stake could be a directional view, one leg of a paired healthcare trade, or a position adjusted after June 30. Griffin has said publicly that Citadel reduced risk this year through large block sales. The firm's third-quarter filing, due by mid-November, will show whether the position was maintained.
AbbVie's investment case rests on its handling of the Humira patent expiration. Humira faced U.S. biosimilar competition from 2023, and its sales have fallen sharply. AbbVie's successors, Skyrizi and Rinvoq, have more than replaced Humira's peak sales. In the second quarter of 2026, Skyrizi generated about $5.5 billion, up 24% year over year, Rinvoq about $2.5 billion, up nearly 24%, and total revenue about $17 billion, up 10%. Management has raised its full-year forecast twice this year, now calling for revenue of about $67.6 billion and adjusted earnings of $13.87 to $14.07 per share, with neuroscience expected to contribute about $12.7 billion.
In late September the FDA approved Juvmo (tavapadon), a once-daily oral Parkinson's treatment that came from AbbVie's 2024 acquisition of Cerevel Therapeutics. Roopal Thakkar, AbbVie's chief scientific officer, called it the first dopaminergic breakthrough for Parkinson's disease in decades. Some analysts expect annual sales of up to $1.4 billion by 2040. AbbVie also has about 90 programs in development, roughly two-thirds in late-stage trials. The stock pays a quarterly dividend of $1.73, or $6.92 annually, a yield of about 2.4%, and the company has raised its dividend for more than 50 consecutive years. On adjusted guidance the shares trade near 20 times this year's earnings, though the trailing P/E of about 74 is distorted by acquisition-related non-cash charges. Of 30 analysts tracked by one major platform, 24 rate the stock a buy or strong buy.
The article identifies several counterweights: low-single-digit price erosion in immunology as AbbVie negotiates 2027 U.S. payer contracts, Inflation Reduction Act Medicare price negotiation risk for its largest drugs, soft aesthetics and declining Imbruvica sales, acquisition-related leverage including the Apogee deal, and concentration in Skyrizi and Rinvoq. The article characterizes 13F filings as signals rather than endorsements, and frames healthcare's defensive growth and dividends as a counterbalance to valuation concerns in AI and technology.
The article cautions that quarterly 13F disclosures must be read carefully for a firm like Citadel, where dozens of independent portfolio teams run long and short positions that are often hedged against each other. A 13F reflects only long U.S. equity holdings and certain options at quarter-end, so the AbbVie stake could be a directional view, one leg of a paired healthcare trade, or a position adjusted after June 30. Griffin has said publicly that Citadel reduced risk this year through large block sales. The firm's third-quarter filing, due by mid-November, will show whether the position was maintained.
AbbVie's investment case rests on its handling of the Humira patent expiration. Humira faced U.S. biosimilar competition from 2023, and its sales have fallen sharply. AbbVie's successors, Skyrizi and Rinvoq, have more than replaced Humira's peak sales. In the second quarter of 2026, Skyrizi generated about $5.5 billion, up 24% year over year, Rinvoq about $2.5 billion, up nearly 24%, and total revenue about $17 billion, up 10%. Management has raised its full-year forecast twice this year, now calling for revenue of about $67.6 billion and adjusted earnings of $13.87 to $14.07 per share, with neuroscience expected to contribute about $12.7 billion.
In late September the FDA approved Juvmo (tavapadon), a once-daily oral Parkinson's treatment that came from AbbVie's 2024 acquisition of Cerevel Therapeutics. Roopal Thakkar, AbbVie's chief scientific officer, called it the first dopaminergic breakthrough for Parkinson's disease in decades. Some analysts expect annual sales of up to $1.4 billion by 2040. AbbVie also has about 90 programs in development, roughly two-thirds in late-stage trials. The stock pays a quarterly dividend of $1.73, or $6.92 annually, a yield of about 2.4%, and the company has raised its dividend for more than 50 consecutive years. On adjusted guidance the shares trade near 20 times this year's earnings, though the trailing P/E of about 74 is distorted by acquisition-related non-cash charges. Of 30 analysts tracked by one major platform, 24 rate the stock a buy or strong buy.
The article identifies several counterweights: low-single-digit price erosion in immunology as AbbVie negotiates 2027 U.S. payer contracts, Inflation Reduction Act Medicare price negotiation risk for its largest drugs, soft aesthetics and declining Imbruvica sales, acquisition-related leverage including the Apogee deal, and concentration in Skyrizi and Rinvoq. The article characterizes 13F filings as signals rather than endorsements, and frames healthcare's defensive growth and dividends as a counterbalance to valuation concerns in AI and technology.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.